echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > PARP inhibitor re-starts phase 0 clinical trials

    PARP inhibitor re-starts phase 0 clinical trials

    • Last Update: 2021-12-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    news

    news

    Recently, Glaxo started a phase 0 clinical trial of GBM, the PARP inhibitor niraparib (trade name Zejula) acquired from Tesaro


    Drug source analysis

    Drug source analysis

    Everyone knows that there are usually three phases of clinical trials before drugs are marketed, but before the emergence of the accelerated approval system, only phase three clinical trials are the real big test


    AbbVie's PARP inhibitor Veliparib became the first drug to take a crab, and completed the first phase 0 clinical trial of a tumor drug.


    There are special reasons why PARP inhibitors have returned to the old industry and started phase 0 clinical trials, which are importantly different from the peripheral drug concentration and activity observed by Veliparib


    In terms of molecular mechanism, PARP inhibitors inhibit DNA repair, and the two GBM pillars of TMZ and radiotherapy induce DNA damage to form a pinch.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.